Skip to main content

Table 3 Summary of treatment-related AEsa

From: Moxetumomab pasudotox in heavily pre-treated patients with relapsed/refractory hairy cell leukemia (HCL): long-term follow-up from the pivotal trial

 

Treatment-related AEs of all grades

Grade 3–4 treatment-related AEs

Patients, n (%)

Patients, n (%)

Nausea

22 (28)

2 (3)

Edema peripheral

21 (26)

0

Headache

17 (21)

0

Pyrexia

16 (20)

1 (1)

Capillary leak syndrome

7 (9)

2 (3)

Hemolytic uremic syndrome

6 (8)

4 (5)

Lymphocyte count decreased

6 (8)

6 (8)

Anemia

5 (6)

2 (3)

Platelet count decreased

5 (6)

2 (3)

Hypertension

4 (5)

2 (3)

Acute kidney injury

2 (3)

2 (3)

Neutropenia

2 (3)

2 (3)

White blood cell count decreased

2 (3)

2 (3)

  1. AE adverse event
  2. aAdverse events of any grade with an incidence of at least 20%, as well as events of grade 3 or 4 with an incidence of at least 3%